Apimeds Pharmaceuticals US, Inc.
APUS- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001894525
No open-market purchases or sales by Apimeds Pharmaceuticals US, Inc. insiders were filed in the last 90 days; 7 institutions reported holding it in 13F filings for Q2 2026, worth $383.7K in total; no superinvestor holds it.
Q2 2025 vs. Q1 2025
How the institutions holding Apimeds Pharmaceuticals US, Inc. changed between Q1 2025 and Q2 2025.
All holders in Q2 2025All holders in Q1 2025
| Measure | Q1 2025 | Q2 2025 | Change |
|---|---|---|---|
| Holders | 0 | 6 | +6 |
| Shares | 0 | 278.5K | +278.5K |
| Value | $0 | $490.2K | +$490.2K |
New holders (6)
Institutions that held Apimeds Pharmaceuticals US, Inc. at the end of Q2 2025 but not at the end of Q1 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Yorkville Advisors Global, LP | 250,000 | $440.0K | 0.23% |
| Citadel Advisors LLC | 13,359 | $23.5K | 0.00% |
| Goldman Sachs Group Inc | 11,987 | $21.1K | 0.00% |
| Tower Research Capital LLC (TRC) | 3,151 | $5.55K | 0.00% |
| Bank of America Corp | 29 | $52 | 0.00% |
| JPMorgan Chase & Co | 5 | $9 | 0.00% |
Sold out (0)
Institutions that held Apimeds Pharmaceuticals US, Inc. at the end of Q1 2025 and filed for Q2 2025 without it.
None.